ClinicalTrials.gg
Active, not recruitingNCT07178483NIVAR01Updated Jan 16, 2026

Evaluation of Physical Capacity and Energy Requirements in Patients With Hypoxemic Acute Respiratory Failure

An observational study in Acute Hypoxemic Respiratory Failure, Non Invasive Ventilation (NIV) and Bioimpedance Measurement Capacity, sponsored by Hospital Universitari de Bellvitge. Active, not recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Hospital Universitari de Bellvitge · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Respiratory Insufficiency with a site in Spain — 11 open to participants now, 15 under way, none of them phase 3. Respiratory Insufficiency · Spain.

Planned enrollment
10th of 31
500 · median 298
Started
2025
with 4 others
Observational
31 of 69
5 open now
Primary completion
2027-03
later than 7 of 14 live
Registered
62nd of 69
by date
Lead sponsor
2 of 69
Hospital Universitari de Bellvitge

Among the 69 studies in Respiratory Insufficiency with a site in Spain, this one is the 10th largest by planned enrollment of the 31 observational ones that give a count, is one of 5 that started in 2025, is one of 31 observational ones, reaches primary completion later than 7 of the 14 other live ones, and was the 62nd registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

11 of the 69 studies in Respiratory Insufficiency with a site in Spain are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Respiratory Insufficiency with a site in Spain, or all of them as a file.
02

Study summary

NIVAR01 (Multimodal evaluation of physical capacity and energy requirements in patients with hypoxemic acute respiratory failure and community acquired pneumonia under non invasive ventilation support) aims to comprehensively assess energy requirements and physical capacity in patients with acute hypoxemic respiratory failure (AHRF) due to community-acquired pneumonia (CAP) undergoing non-invasive ventilation (NIV).

Through a stepwise, multimodal approach integrating physiological measurements, imaging, and molecular biomarkers, the project seeks to identify patient subphenotypes that can guide targeted interventions, improve outcomes, and reduce the need for invasive mechanical ventilation. The project is structured in five progressive phases, each building on the findings of the previous one to refine and personalize care strategies.

The first phase of the project aims to assess the correlation between BIA (bioelectrical impedance analysis) and IC (indirect calorimetry) in sedated patients, in oder to extrapolate this correlation in patients under NIV in the next phase.

The second phase uses this correlation to validate the use of indirect calorimetry (IC) in patients under non-invasive ventilation (NIV) by comparing it with data obtained from patients under invasive mechanical ventilation, where IC is better established and technically more accurate. This comparative approach will serve to assess the reliability and feasibility of IC in NIV settings, incorporating correction factors for air leaks and comparing with BIA data, laying the groundwork for its integration with other physiological and biochemical measurements in subsequent phases.

The third phase expands to a multimodal prospective observational cohort study integrating IC, BIA, ultrasound, biomarkers of mitochondrial and endothelial dysfunction, and innate immune system paralysis. These data will be used for patient phenotyping through advanced machine learning. The fourth and fifth phases will develop and test personalized nutritional and motor interventions (e.g., phrenic nerve stimulation, tailored physiotherapy) in clinical trials based on identified patient subtypes.

Previous studies (Georges et al., Siirala et al., Singer 2024) have demonstrated the feasibility of using IC in NIV patients, although limited by methodological constraints. This project brings novelty by incorporating BIA-derived metabolic rate estimates and segmental analysis, offering new insights into body composition, fluid balance, and muscle integrity, including diaphragm function.

Additionally, biomarkers such as cf-mtDNA, FGF-21, GDF-15, HSP60/10, and cytokine profiles (TNFα, IL-6, IL-10, CRP), as well as endothelial markers (e-Selectin, sICAM-1, vCAM-1, Syndecan-1), will be analyzed. Immune paralysis will be studied via monocyte HLA-DR expression and LPS-stimulated cytokine release.

By leveraging multimodal data integration and gender-specific analysis, NIVAR 01 aims to optimize prediction of NIV failure beyond current tools such as the HACOR index and enable individualized patient management.

Read the detailed description

Non-invasive ventilation (NIV) is widely used in patients with acute hypoxemic respiratory failure (AHRF), particularly those with community-acquired pneumonia (CAP), as a strategy to avoid intubation and invasive mechanical ventilation. However, predicting NIV failure remains a significant clinical challenge, and the existing tools, such as the HACOR index, are limited in accuracy and do not take into account crucial aspects like energy expenditure, muscle integrity, or other patient's physiological parameters.

NIVAR01 addresses this gap through a comprehensive, stepwise research plan aimed at understanding and anticipating NIV failure by integrating metabolic, physiological, imaging, and biomolecular data. The ultimate goal is to define patient subphenotypes that enable the personalization of therapy and improve clinical outcomes.

Objectives

The main objective of NIVAR 01 is to develop and validate a multimodal strategy to predict NIV failure in patients with AHRF and CAP, enabling the design of personalized therapeutic interventions. Specifically, the project aims to:

  • Validate the use of indirect calorimetry during NIV and its correlation with BIA.
  • Identify physiological and molecular phenotypes associated with NIV failure.
  • Develop and test targeted nutritional and functional interventions based on patient subtypes.

Planning

The project is structured in five sequential phases, each building upon the results of the previous one. The approach moves from methodological validation to biological characterization and finally to clinical intervention. It will integrate sex-specific analysis into predictive models and intervention strategies.

- Phase 1: Correlation between BIA and IC in sedated patients

The project begins by evaluating the correlation between metabolic rate data obtained from BIA and from indirect calorimetry in sedated, invasively ventilated ICU patients. Since IC is a robust validated method in this setting, it will serve as the reference method. The correlation obtained will validate the accuracy of BIA and support its use in future phases.

- Phase 2: Validation of IC in patients under NIV

Using the reference from Phase 1, IC will be adapted for use in patients under NIV. This includes addressing the challenges posed by air leaks through integration of correction factors provided by ventilator device and its monitoring software, and potentially the development of specific circuit adaptors if required. The metabolic data collected via IC will be compared with BIA estimates to confirm feasibility and reliability in the NIV setting.

- Phase 3: Multimodal cohort study and patient phenotyping

In a prospective observational study, a cohort of patients with AHRF and CAP under NIV will undergo multimodal evaluation. This includes IC, BIA (with segmental analysis of the different body compartments both at the anatomic and physiological level), muscle and diaphragm ultrasound, and blood sampling for biomarkers of mitochondrial dysfunction (cf-mtDNA, FGF-21, GDF-15, HSP60/10), endothelial injury (e-Selectin, sICAM-1, vCAM-1, Syndecan-1), oxidative stress, and immune paralysis (HLA-DR expression, TNFα response to LPS). Data will be analyzed using machine learning to identify patient subphenotypes.

- Phase 4: Design of personalized interventions

Based on the phenotypes identified, targeted interventions will be developed. These include nutritional strategies informed by metabolic requirements and muscle function assessments, as well as physiotherapy protocols that may involve early mobilization and respiratory muscle stimulation (e.g., phrenic nerve). Strategies will be adapted to sex-specific physiological patterns and the patient's compartmental body composition.

- Phase 5: Randomized controlled trials

In the final phase, the proposed interventions will be tested in randomized clinical trials (RCTs). Patients will be stratified by phenotype and randomized to receive standard care or personalized therapy. Primary outcomes will include NIV failure (need for intubation), ICU/hospital length of stay, mortality, and functional recovery.

Expected Outcomes

NIVAR 01 is expected to generate:

  • A validated protocol for using IC during NIV, including leak correction methods.
  • Evidence supporting the use of BIA as a practical bedside tool to estimate metabolic rate and assess muscle and fluid status.
  • Identification of subphenotypes among AHRF patients under NIV, based on multimodal data integration.
  • Personalized intervention protocols tailored to patient profiles, with demonstrated clinical benefit in RCTs.
  • New predictive models that outperform traditional tools like the HACOR index.
  • Practical contributions to gender-informed critical care.

This integrated model will help clinicians anticipate NIV failure earlier, adapt treatment proactively, and improve patient outcomes through individualized care strategies.

Conclusion

NIVAR01 aims to develop a new standard in the management of patients with acute respiratory failure under non-invasive ventilation. By combining validated physiological measurements, molecular biomarkers, and clinical decision tools, the project introduces a precision medicine approach to intensive care. Through systematic validation, rigorous phenotyping, and targeted interventions, NIVAR 01 aims to reduce NIV failure, shorten ICU stays, and improve survival and recovery in this patient population.

03

Conditions studied

  • Acute Hypoxemic Respiratory Failure
  • Non Invasive Ventilation (NIV)
  • Bioimpedance Measurement Capacity
  • Calorimetry, Indirect
  • Muscular Ultrasound
  • Mitochondrial Biomarkers
  • Endotheliopathy
  • Immune Response
  • Community Acquired Pneumonia (CAP)

Keywords

  • NIV
  • ARF
  • BIOIMPEDANCIOMETRY
  • INDIRECT CALORIMETRY
  • CAP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients admitted to critical care units requiring NIV support due to CAP and hypoxemic acute respiratory failure.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate-to-severe Acute Hypoxemic Respiratory Failure (PaO2 /FiO2 \< 200mmHg) due to respiratory infection who underwent NIV support for at least 24h.

Exclusion criteria

Exclusion Criteria:

  • Presence of electrical implants, wounds or skin damage at the designated electrode sites or the inability to perform BIA.
  • Patients who met criteria for immediate intubation upon ICU admission were also excluded.
  • Other circumstances or clinical conditions at the discretion of the investigator that precluded the participation of the patient in the study were also considered (i.e., limitation of therapeutic effort and poor prognosis).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
1 Month
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. NIV FAILURE

    ENDOTRACHEAL INTUBATION OR DEATH WHILE RECEIVING NIV

    Time frame: 1 MONTH

Secondary outcomes

  1. ICU LENGHT OF STAY

    DAYS IN ICU WILL BE REGISTERED.

    Time frame: Through study completion, an average of 1 year

  2. HOSPITAL LENGTH OF STAY

    DAYS ADMITTED IN HOSPITAL

    Time frame: Through study completion, an average of 1 year.

07

Study locations

1 site
08

References and documents

Publications

  • Moonen HPFX, Van Zanten ARH. Bioelectric impedance analysis for body composition measurement and other potential clinical applications in critical illness. Curr Opin Crit Care. 2021 Aug 1;27(4):344-353. doi: 10.1097/MCC.0000000000000840. PubMed 33967207 ↗
  • Cunningham JJ. Body composition as a determinant of energy expenditure: a synthetic review and a proposed general prediction equation. Am J Clin Nutr. 1991 Dec;54(6):963-9. doi: 10.1093/ajcn/54.6.963. PubMed 1957828 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.

Of 232 non-industry observational studies under Respiratory Insufficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's planned 24 months is close to that.

Counting every sponsor, half of 248 studies reached it within 22 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2025
First posted
Sep 17, 2025
StartActual
Mar 1, 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07178483
Responsible party
JOSE LUIS PEREZ FERNANDEZ (PhD, Hospital Universitari de Bellvitge) — Principal investigator
First posted
Sep 17, 2025
Start date
Mar 1, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Jan 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion